Drug profile · INN
acetohydroxamic acid
LITHOSTAT
acetohydroxamic acid (LITHOSTAT) is a bacterial urease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — acetohydroxamic acid
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
acetohydroxamic acid (LITHOSTAT) is a bacterial urease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial urease inhibitor
Primary target: Bacterial urease
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is acetohydroxamic acid?
acetohydroxamic acid (LITHOSTAT) is a bacterial urease inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for acetohydroxamic acid?
LITHOSTAT is a marketed brand name for acetohydroxamic acid. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of acetohydroxamic acid?
acetohydroxamic acid has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.